[Hypertension after kidney transplantation]

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Context:

• Cardiovascular disease (CVD) is the primary cause of mortality in renal transplant recipients.
• Post-transplant arterial hypertension is common and linked to CVD and graft failure.
• Factors include kidney dysfunction and immunosuppressive medications.

Purpose:

• To explore the relationship between immunosuppressive drugs and post-transplant hypertension.
• To identify alternative immunosuppressive strategies to mitigate hypertension.
• To emphasize the importance of managing metabolic disorders post-transplant.

Summary:

• Arterial hypertension is highly prevalent after renal transplantation, influenced by immunosuppressive drugs like corticosteroids, cyclosporine, and tacrolimus.
• Tacrolimus-based therapy may be associated with less hypertension than cyclosporine.
• Newer agents like mycophenolate mofetil and sirolimus are non-nephrotoxic and non-hypertensive, offering alternatives.
• Close monitoring and treatment of dyslipidemia and diabetes are crucial.
• Reducing hypertension incidence involves early detection, adjusted immunosuppression, and aggressive treatment.

Impact:

• Optimizing immunosuppressive protocols can decrease post-transplant hypertension incidence and severity.
• Managing hypertension and metabolic disorders is vital for improving long-term outcomes in renal transplant recipients.
• Identifying safer immunosuppressive drug combinations can reduce cardiovascular risk and enhance graft survival.